safety, tolerability, and monitoring
adverse events, boxed warnings, and what to track during treatment
safety, tolerability, and monitoring
semaglutide carries a well-characterized adverse event profile dominated by GI effects, a boxed warning for thyroid C-cell tumors in rodents, and ongoing surveillance for pancreatitis and lean mass loss. this unit walks through each risk category, the frequency data from pivotal trials, and the monitoring protocols that clinicians and informed users should follow.
the paid sections cover GI event rates by dose, the medullary thyroid carcinoma rodent-to-human translation question, pancreatitis signal interpretation, 20-40% of weight lost coming from lean mass, and the specific monitoring schedule for lipase, thyroid checks, and psychiatric screening.
Interactive Visualization
explore adverse event frequencies by severity and category across the semaglutide trial program.